中国神经再生研究(英文版) ›› 2026, Vol. 21 ›› Issue (4): 1304-1321.doi: 10.4103/NRR.NRR-D-24-01354

• 综述:脊髓损伤修复保护与再生 • 上一篇    下一篇

软骨素酶 ABC 在损伤脊髓修复中的应用趋势

  

  • 出版日期:2026-04-15 发布日期:2025-07-24

Trends in the application of chondroitinase ABC in injured spinal cord repair

Zhongqing Ji1, 2, #, Jiangfeng Zhu2, #, Jinming Liu3, #, Bin Wei2 , Yixin Shen1 , Yanan Hu3, *   

  1. 1 Department of Orthopedics, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China;  2 Department of Orthopedic Surgery, Suzhou Yongding Hospital, Suzhou, Jiangsu Province, China;  3 Department of Cell Biology, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, Jiangsu Province, China
  • Online:2026-04-15 Published:2025-07-24
  • Contact: Yanan Hu, MD, huya_nan_good@126.com.
  • Supported by:
    This work was supported by the National Natural Science Foundation of China, No. 82002645; China Postdoctoral Science Foundation, No. 2022M722321; and Jiangsu Funding Program for Excellent Postdoctoral Talent, No. 2022ZB552 (all to YH).

摘要:

脊髓损伤是一种复杂而令人衰弱的病症,会严重改变患者生活和功能的各个方面在这种情况下,软骨素酶 ABC成为一种很有前景的治疗药物,它是一种从普通变形杆菌(Proteus vulgaris)中分离出来的细菌酶,经过改良后便于在哺乳动物体内表达和分泌。它通过降解硫酸软骨蛋白多糖发挥作用,将硫酸软骨蛋白多糖的糖胺聚糖链裂解为可溶性二糖或四糖。硫酸软骨蛋白多糖是强效的轴突生长抑制剂,也是附着在糖胺聚糖链上的神经胶质细胞和神经细胞周围细胞外基质的主要成分。在各种动物模型中,软骨素酶 ABC通过改善轴突再生和萌发、增强神经元周围网的可塑性、抑制神经元凋亡和调节免疫反应,在促进急性和慢性脊髓损伤恢复方面发挥了有效作用。这篇综述中介绍了脊髓损伤的分类和病理机制,并讨论了硫酸软骨蛋白多糖在脊髓损伤中的病理生理作用。还重点介绍了脊髓损伤治疗策略的研究进展,主要侧重于软骨素酶 ABC,并说明了软骨素酶 ABC 的稳定性、酶活性和给药方法的改进如何促进了脊髓损伤的修复。此外,还强调软骨素酶 ABC的联合治疗将进一步提高疗效。文章目的在于全面了解基于软骨素酶 ABC的脊髓损伤疗法的当前趋势和未来方向,重点关注现代技术如何加速软骨素酶 ABC的优化开发

https://orcid.org/0000-0002-5506-0890 (Yanan Hu)

关键词: 轴突再生, 硫酸软骨素蛋白多糖, 软骨素ABC酶, 联合疗法, 给药方法, 酶活性, 糖胺聚糖链, 脊髓损伤, 稳定性

Abstract: Spinal cord injuries have overwhelming physical and occupational implications for patients. Moreover, the extensive and long-term medical care required for spinal cord injury significantly increases healthcare costs and resources, adding a substantial burden to the healthcare system and patients’ families. In this context, chondroitinase ABC, a bacterial enzyme isolated from Proteus vulgaris that is modified to facilitate expression and secretion in mammals, has emerged as a promising therapeutic agent. It works by degrading chondroitin sulfate proteoglycans, cleaving the glycosaminoglycanchains of chondroitin sulfate proteoglycans into soluble disaccharides or tetrasaccharides. Chondroitin sulfate proteoglycans are potent axon growth inhibitors and principal constituents of the extracellular matrix surrounding glial and neuronal cells attached to glycosaminoglycan chains. Chondroitinase ABC has been shown to play an effective role in promoting recovery from acute and chronic spinal cord injury by improving axonal regeneration and sprouting, enhancing the plasticity of perineuronal nets, inhibiting neuronal apoptosis, and modulating immune responses in various animal models. In this review, we introduce the classification and pathological mechanisms of spinal cord injury and discuss the pathophysiological role of chondroitin sulfate proteoglycans in spinal cord injury. We also highlight research advancements in spinal cord injury treatment strategies, with a focus on chondroitinase ABC, and illustrate how improvements in chondroitinase ABC stability, enzymatic activity, and delivery methods have enhanced injured spinal cord repair. Furthermore, we emphasize that combination treatment with chondroitinase ABC further enhances therapeutic efficacy. This review aimed to provide a comprehensive understanding of the current trends and future directions of chondroitinase ABC -based spinal cord injury therapies, with an emphasis on how modern technologies are accelerating the optimization of chondroitinase ABC development.

Key words: axonal regeneration, chondroitin sulfate proteoglycans, chondroitinase ABC, combination treatments, delivery methods, enzymatic activity, glycosaminoglycan chains, spinal cord injury, stability